| Withdrawn | Determining the Association of Microvascular Disease as Assessed by PET and Graft Injury by Donor Derived Cell NCT05756088 | Yale University | — |
| Not Yet Recruiting | Comparing PCCT With ICA and IVUS in Detecting Cardiac Allograft Vasculopathy NCT07020039 | Sahlgrenska University Hospital | — |
| Recruiting | MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation NCT06089486 | Ottawa Heart Institute Research Corporation | N/A |
| Enrolling By Invitation | Impact of SGLT2 Inhibitors in Heart Transplant Recipients NCT06147271 | Universidade Federal do Ceara | Phase 2 |
| Completed | Unraveling Mechanism of Action of Extracorporeal Photopheresis in Heart and Lung Transplant Patients NCT06899828 | Fondazione IRCCS Policlinico San Matteo di Pavia | — |
| Recruiting | Microvascular Cardiac Allograft Vasculopathy Trial NCT05826444 | German Heart Institute | — |
| Completed | Endothelin-1 and Cardiac Allograft Vasculopathy (CAV) NCT05373108 | University of California, Los Angeles | Phase 4 |
| Recruiting | AERIAL Trial: Antiplatelet Therapy in Heart Transplantation NCT04770012 | Ottawa Heart Institute Research Corporation | Phase 3 |
| Unknown | Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant R NCT04193306 | Institute for Clinical and Experimental Medicine | Phase 4 |
| Completed | Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Rec NCT03734211 | Lars Gullestad | Phase 3 |
| Unknown | Cardiac Mitochondrial Function After Heart Transplantation NCT04105803 | University of Aarhus | — |
| Completed | Potential Role of Donor-derived Cell-Free DNA as a Biomarker in Cardiac Allograft Vasculopathy NCT04791852 | Puerta de Hierro University Hospital | — |
| Unknown | Heart Failure After Heart Transplantation Due to Chronic Rejection NCT03808324 | Sahlgrenska University Hospital | N/A |
| Unknown | Effect of Ivabradine on Exercise Capacity After Heart Transplantation NCT03405831 | Finn Gustafsson | Phase 4 |
| Active Not Recruiting | Early Post Transplant Cardiac Allograft Vasculopathy NCT03217786 | Ottawa Heart Institute Research Corporation | — |
| Unknown | Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score NCT03386539 | Boston Children's Hospital | Phase 3 |
| Completed | Extracorporeal Photopheresis and Early Cardiac Graft Vasculopathy NCT04226521 | Bosko Skoric | N/A |
| Completed | Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy NCT02880137 | Mayo Clinic | Phase 4 |
| Recruiting | Physiologic Assessment of Microvascular Function in Heart Transplant Patients NCT02798731 | Samsung Medical Center | — |
| Completed | Safety and Efficacy of Everolimus - Eluting Bioresorbable Vascular Scaffold for Cardiac Allograft Vasculopathy NCT02377648 | Universita di Verona | Phase 4 |
| Completed | A P2X7R Single Nucleotide Mutation Promotes Chronic Allograft Vasculopathy NCT02082821 | Boston Children's Hospital | — |
| Completed | The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation NCT02013037 | Cedars-Sinai Medical Center | Phase 3 |
| Terminated | Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation NCT01848301 | Gladwin, Mark, MD | Phase 1 |
| Withdrawn | Severe CAV MRI in Heart Transplant Recipient NCT02777255 | University of Minnesota | — |
| Terminated | Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation NCT01278745 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Optical Coherence Tomography (OCT) to Evaluate Cardiac Allograft Vasculopathy (CAV) in Patient's Post Heart Tr NCT01403142 | Columbia University | — |
| Completed | Assessment of Cardiac Allograft Vasculopathy With Optical Coherence Tomography NCT01527344 | Mayo Clinic | — |
| Unknown | Identification of Non Invasive Biomarkers of Immune Endothelial Injury and Repair Associated With Cardiac Allo NCT01569334 | Assistance Publique Hopitaux De Marseille | N/A |
| Withdrawn | Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients NCT01305395 | University of Minnesota | N/A |
| Withdrawn | A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Prev NCT01157949 | Cedars-Sinai Medical Center | Phase 3 |
| Withdrawn | Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients NCT01812434 | University of Minnesota | N/A |
| Completed | Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation NCT01186250 | Stanford University | Phase 2 |
| Completed | Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy NCT01078363 | Stanford University | N/A |
| Unknown | Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy NCT00966836 | University of Bologna | Phase 3 |
| Completed | HEart trAnsplantation Registry of piTie-Salpetriere University Hospital NCT03393793 | Lee S Nguyen | — |
| Withdrawn | Noninvasive Evaluation of Cardiac Allograft Vasculopathy NCT01305382 | University of Minnesota | — |
| Withdrawn | Noninvasive Predictors of Transplant Vasculopathy NCT01424917 | University of Minnesota | — |